GB2501242A - A composition for the treatment of obesity - Google Patents

A composition for the treatment of obesity Download PDF

Info

Publication number
GB2501242A
GB2501242A GB1205152.0A GB201205152A GB2501242A GB 2501242 A GB2501242 A GB 2501242A GB 201205152 A GB201205152 A GB 201205152A GB 2501242 A GB2501242 A GB 2501242A
Authority
GB
United Kingdom
Prior art keywords
weight
composition according
carnitine
chitosan
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1205152.0A
Other versions
GB201205152D0 (en
Inventor
Ajit Ramanial Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1205152.0A priority Critical patent/GB2501242A/en
Publication of GB201205152D0 publication Critical patent/GB201205152D0/en
Publication of GB2501242A publication Critical patent/GB2501242A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

A composition for oral ingestion comprises powdered plant material from Opuntia ficus indica, glucomannan, chitosan, L-carnitine and a chromium (III) compound. The chromium compound may be chromium (III) picolinate. The composition is suitable for reducing cravings for fat, the absorption of fats from the gastrointestinal tract, reducing fat mass in the body, and the treatment of obesity.

Description

A COMPOSITION FOR REDUCING FAT ACCUMULATION IN THE BODY
This invention relates to a composition for reducing the motivation to ingest fat, the absorption of fats from the gastrointestinal tract, and reducing fat mass in the body.
Background of the invention
The incidence of obesity has increased dramatically over the past few decades in most developed countries and one reason for this has been a very large increase in the amount of fat consumed by the average member of the public. A great many solutions to this problem have been proposed ranging from special diets and exercise regimes, lipid-reducing food supplements and diet-suppressing drugs to surgical interventions such as gastric bands.
Various natural, semi-synthetic and synthetic substances have been developed and used for the purpose of binding lipids in the gastrointestinal (Cl) tract in order to reduce or prevent absorption of the lipids. For example, synthetic polymeric resins, which may be polyamines or anionic polymeric resins, have been proposed and used for binding to bile acids thereby preventing their reuptake and use in the biosynthesis of cholesterol. Examples ot substances of this type are disclosed in GB929391 (Merck). A problem with bile acid sequestering resins has been their lack of palatability. Consequently, much research has been expended in finding combinations of the resins with agents that improve the palatability of the resins.
For example, US5601837 discloses combinations of psyllium husk and cholestyramine for treating hypercholesterolemia. US5286481 discloses combinations of an anion-exchange resin such as cholestyramine, colestipol or polidexide and bran for use in weight-reduction.
Other examples of substances for use in binding bile acids or other lipids such as triglycerides are disclosed in DE4136325 (Hoechst), which discloses cyclodextrins as bile acid adsorption agents useful for treating hyperlipidaemia, and US2004/0126444 (Dallas et at), which discloses the use of powdered plant material from the cladodes of cacti, including from the genus Opuntia, for binding dietary fats.
Chitosan has been used for binding and preventing the absorption of dietary fats.
Chitosan is a deacetylated form of chitin, an amino polysaccharide (poly-N-acetyl glucosamine) found in the exoskeleton of arthropods (e.g., crustaceans such as lobsters and crabs) and also found in some plants and fungi. Chitosan is similar in structure and properties to dietary fibre (e.g., vegetable bran, cellulose) but, unlike like bran and cellulose, chitosan has the ability to bind fat and other lipids in the intestine. A known problem with chitosan, as disclosed in W099121 566 (Rexall Sundown), is that when chitosan is consumed in the quantities required for dietary fat reduction, constipation can result. Indeed, W099/21566 discloses that the use of chitosan as a dietary supplement must be of short duration or other ingredients or supplements added to combat the undesirable effects of the chitosan.
W099/21 566 proposes the addition of aloin, which contains aloe saponins, in order to offset the constipating effect of chitosan. US4999341 discloses the use of soy saponins to offset the constipating effect of the chitosan. U5200710048392 (Oben) discloses the use of combinations of chitosan and a plant extract from a plant of the Cissu.s, Vernon/a or Brillantasia families.
Glucomannan is a water soluble polysaccharide comprising mainly of mannose and glucose linked by beta 1,4 glycosidic bonds, typically in a ratio of 8:5. It is considered a dietary fibre and is used as a food additive as an emulsifier and thickener. It is marketed as a nutritional supplement directed towards obesity, high cholesterol and type 2 diabetes. Glucomannan has been shown to decrease serum cholesterol when used in combination with chitosan, possibly by increasing steroid excretion via the faeces. Glucomannan is hygroscopic and on hydration, glucomannan forms a viscous gel, absorbing up to 50 times its weight in water.
Glucomannan expands on hydration, enhancing satiation when taken with a meal.
However, a problem with using glucomannan is that, due to its swelling properties, great care must be taken when ingesting glucomannan, especially in high doses, to avoid Cl tract blockage.
Thus, at present, numerous substances and combinations of substances have been used for binding dietary lipids in the Cl tract so as to prevent uptake of the lipids, and other substances are thought to suppress cravings for dietary fat or reduce fat mass in the body. However, there is a need for an improved composition comprising substances that work together to reduce the accumulation of fats by reducing fat ingestion, absorption and aggregation, whilst avoiding the problems of Cl tract blockage and constipation caused by many known lipid-binding products.
Summary of the invention
The present invention provides an improved composition for binding dietary lipids in the GI tract and thereby preventing or reducing absorption of the lipids, reducing the motivation for ingestion of lipids and reducing the aggregation of fat mass in the body. In this way, the compositions provide a means of combatting obesity and hyperlipidaemia.
Accordingly, in a first aspect, the invention provides a composition for oral ingestion comprising powdered plant material from Opuntia ficu.s md/ca, glucomannan, chitosan, L-carnitine and a chromium (Ill) compound such as chromium (Ill) picolinate.
Thus, the invention provides a composition that advantageously reduces lipid accumulation in the body via three separate mechanisms, which enables each component of the composition to be administered at reduced levels compared to single-component compositions or compositions in which each component acts via the same mechanism (e.g. compared to compositions consisting of two or more gelling agents). This, in turn, reduces undesirable effects associated with taking large doses of a single component or class of components.
The properties of Opuntia ficu.s md/ca, glucomannan and chitosan are as described above.
L-carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine. L-carnitine is particularly enriched in red meat and dairy products. L-carnitine is involved in cellular transport of fatty acids relating to lipid metabolism.
The chromium (Ill) compound is typically a chromium (Ill) salt or coordination complex, preferably chromium (Ill) picolinate. Chromium (Ill) picolinate may be prepared by aqueous reaction of chromium (Ill) chloride with three equivalents of picolinic acid, and is commercially available from Intatrade Chemicals GmbH, Germany. In the context of the present invention, the chromium compound (e.g. chromium picolinate) is believed to control cholesterol levels and decrease cravings for the ingestion of fat.
The composition may comprise from 65-SO % by weight of chitosan, 4-10% by weight of the powdered plant material from Opuntia ficus indica, 4-10% by weight glucomannan, 12-16% by weight of L-carnitine and 0.010-0.020% by weight of a chromium (Ill) compound.
In one embodiment, the composition comprises from 68-78 % by weight of chitosan, 5-8% by weight of the powdered plant material from Opuntia ficus indica, 5-8% by weight glucomannan, 13-15% by weight of L-carnitine and 0.01 2-0.016% by weight ofa chromium (Ill) compound.] In another embodiment, the composition contains from 0.5 to 1.5 parts by weight of the powdered plant material from Opuntia ficus md/ca, from 0.5 to 1.5 parts by weight of glucomannan from 5 to 15 paris by weight of chitosan, from ito 3 parts by weight L-carnitine and from 0.001 to 0.003 pads by weight chromium compound.
More particularly, the composition may contain from 15 mg to 50 mg of the powdered plant material from Opuntia f/cus md/ca, from 15 mg to 50 mg of the glucomannan, from 150 mg to 500 mg of the chitosan, from 30mg to 100mg of the L-carnitine and from 30 pg to 0.1 mg of the chromium compound.
For example, the composition may contain from 25 mg to 45 mg of the powdered plant material from Opuntla ticus indica, from 25 mg to 45 mg of the glucomannan, from 250 mg to 450 mg of the chitosan, from 50 mg to 85 mg of the L-carnitine and from 50 pg to 0.1 mg of the chromium compound.
In one preferred embodiment, the composition contains from approximately 30 mg of the powdered leaf material from Opuntia ficus indica, approximately 30 mg of the glucomannan, approximately 350 mg of the chitosan, approximately 67mg of the L-carnitine and approximately 67 pg of the chromium compound.
Compositions of the invention advantageously enable the proportions of the components that swell on hydration to be reduced by including in the formulation compounds that reduce fat intake and fat mass. Thus, the compositions of the inventions are believed to help reduce obesity, while reducing the risk of GI tract occlusionlconstipation.
The compositions of the invention may be presented in the form of capsules.
The compositions of the invention may also be presented as medical devices, the term medical device as used herein referring to a substance which whilst providing a medical benefit to a subject, is not absorbed significantly from the subject's GI tract and does not exert its actions by pharmacological means.
The composition, capsule or medical device of the invention as defined herein may be used for one or more of: binding lipids passing through the gastrointestinal tract and thereby preventing or reducing absorption of the lipids; reducing the cravings for fat; and reducing fat mass in the body.
The composition, capsule or medical device of the invention as defined herein may be used for reducing obesity.
The invention provides a composition for use in the treatment of obesity.
The invention provides a method of reducing obesity comprising administration of a corriposition, capsule or medical device of the invention.
The invention further provides a method of assisting weight loss comprising administration of a composition, capsule or medical device of the invention.
The invention additionally provides use of a composition of the invention for the manufacture of a medicament for treating obesity.
Glucomannan may be obtained from derived from konjac root (Amorphophallus konjac). In the compositions of the present invention, the glucomannan may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99,5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% byweightofthe particles have a particle size (e.g. diameter) of 210 pM or less.
Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
The term "glucomannan" as used herein may refer to pure and substantially pure glucomannan, or may refer to material comprising glucomannan and other material from plant sources from which the glucomannan is derived, e.g. from konjac.
The chitosan used in the compositions of the present invention is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (crabs, shrimp, etc.) and cell walls of fungi. The degree of deacetylation is typically in the range 60-100 %, for example from 50-90% or 60- 80%. The average molecular weight of the chitosan is typically between 3,800 and 20,000 daltons, for example from 5,000 to 15,000 daltons, or from 5,000 to 10,000 daltons, or from 7,500 to 12,500 daltons.
The chitosan is presented in the form of a powder. The chitosan may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5°Io by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
Opuntia ficus Thdica is a cactus found in Central and South America. The cactus produces "cladodes" or truncated branches of the stem that contain chlorophyll and are adapted to carry out photosynthesis. The cladodes have a leaf-like appearance but are not true leaves. In the present context, the term "leaf material from Opuntia ficus indica" refers to the cladodes.
The term "plant material" includes material derived from the cladodes or from other parts of the plant such as the plant stem.
In one preferred embodiment, the plant material is derived from the cladodes or leaves of the plant.
The cladodes or other parts of the plant are dried and then ground to a powder in which at least 99.5% by weight of the particles have a maximum dimension (e.g. diameter) of less than 300 pM. More typically, at least 70% by weight of the particles have a maximum dimension (e.g. diameter) of less than 100 pM.
Further details of the preparation of powdered plant material from Opuntia ficus indica may be found in US2004/0126444.
The plant material is presented in the form of a powder. The plant material may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less.
Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
In the compositions of the present invention, the L-carnitine may be presented in powder form.
The L-carnitine may be presented in compositions of the present inventions in the form of L-carnitine L-tartrate.
In the compositions of the present invention, the chromium compound may be presented in powder form.
The chromium compound may be present in compositions of the present inventions in the form of chromium (Ill) picolinate or chromium (Ill) nicotinate, preferably chromium (Ill) picolinate.
The compositions of the invention are typically administered with or without (but preferably with or shortly before or after) meals one or more times per day. For example, the compositions may be administered from two to four times per day.
The compositions may be administered so that the daily intakes of the five components are as follows: Powdered plant material from Opuntia ficus indica: 10 mg to 0.5 g Glucomannan: 10 mg to 0.5 g Chitosan: 0.1 g to 5 g L-carnitine: 20 mg to 1 g Chromium compound: 10 pg to I mg The compositions of the invention bind fats and other lipids in the GI tract and carry S them through so that they are excreted with the faeces. In this way, the fats and other lipids cannot be absorbed by the body. By mopping up a large proportion of the fats in food consumed by a subject, obesity and hyperlipidaemia may be prevented.
The compositions of the invention may also enhance the level of dietary fibre in a subject's diet, thus improving the passage of waste through the digestive tract, reducing constipation and enhancing the well-being of a subject. The compositions of the invention may additionally increase the feeling of satiation when taken with a meal, thus reducing the amount of food consumed by a subject, thereby potentially reducing obesity.
The invention will now be illustrated, but not limited, by reference to the following
specific example.
EXAMPLE 1
Capsule formulation I A two-part capsule shell formed from hydroxypropyl methylcellulose is filled with a mixture of Opuntia ficu.s indica powder, glucomannan powder, chitosan powder, L-carnitine and chromium in the following proportions: Opuntia f/otis indica powder: 33 mg Glucomannan: 33 mg Chitosan: 350 mg L-carnitine L-tartrate: 67 mg Chromium (Ill) picolinate: 67 pg The capsules are taken as a food supplement, three capsules being administered with each meal up to a total of six capsules per day.
It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.

Claims (24)

  1. CLAIMS1. A composition for oral ingestion comprising powdered plant material from Opuntia ficus indica, glucomannan, chitosan, L-carnitine and a chromium (Ill) compound.
  2. 2. A composition according to claim 1 comprising from 65-80 % by weight of chitosan, 4-10% by weight of the powdered plant material from Opuntia ficus indica, 4-10% by weight glucomannan, 12-16% by weight of L-carnitine and 0.010-0.020% byweightofa chromium (Ill) compound.
  3. 3. A composition according to claim 2 comprising from 68-78 % by weight of chitosan, 5-8% by weight of the powdered plant material from Opuntia ficus indica, 5-8% by weight glucomannan, 13-15% by weight of L-carnitine and 0.012-0.016% by weight of a chromium (Ill) compound.
  4. 4. A composition according to claim 1 comprising from 0.5 to 1.5 parts by weight of the powdered plant material from Opuntia ficus indica, from 0.5 to 1.5 pads by weight of glucomannan, from 5 to 15 pads by weight of chitosan, from 1 to 3 pads by weight of L-carnitine and from 0.001 to 0.003 parts by weight of the chromium compound.
  5. 5. A composition according to claim 4 containing from 15mg to 50mg of the powdered plant material from Opuntia ficus indica, from 1 5 mg to 50 mg of the glucomannan, from 150 mg to 0.5 g of the chitosan, from 30 mg to 100 mg of the L-carnitine and from 30 pg to 0.1 mg of the chromium compound.
  6. 6. A composition according to claim 5 containing from 25 mg to 45 mg of the powdered plant material from Opuntia ficus indica, from 25 mg to 45 mg of the glucomarinan, from 250 mg to 350 mg of the chitosan, from 50 mg to 85 mg of the L-carnitine and from 50 pg to 80 pg of the chromium compound.
  7. 7. A composition according to claim 6 containing approximately 30mg of the powdered plant material from Opuntia ficus indica, approximately 30 mg of the glucomannan, approximately 350 mg of the chitosan, approximately 70mg of the L-carnitine and approximately 70 pg of the chromium compound.
  8. 8. A composition according to any one of claims 1 to 7 wherein the powdered plant material from Opuntia ficus indica is derived from leaves or cladodes of the plant.
  9. 9. A composition according to any one of claims ito 8 wherein the powdered plant material from Opuntia ficus indica is present in the form of a powder in which at least 76% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  10. 10. A composition according to any one of claims I to 9 wherein the powdered glucomannan is present in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  11. 11. A composition according to any one of claims Ito iO wherein the chitosan is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  12. 12. A composition according to any one of claims i to 11 wherein the L-carnitine is present in the form of a powder.
  13. 13. A composition according to any one of claims ito 12 wherein the L-carnitine is present in the form of L-carnitine L-tartrate.
  14. 14. A composition according to any one of claims I to 13 wherein the chromium compound is present in the form of a powder
  15. 15. A composition according to any one of claims ito 14 wherein the chromium compound is chromium (Ill) picolinate.
  16. 16. A composition according to any of claims ito i5 containing 33mg of the powdered plant material from Opuntia ficus indica, 33 rig of the powdered glucomannan, 350 mg of the chitosan, 67 mg of the L-carnitine L-tartrate and 67 pg of the chromium (Ill) picolinate.
  17. i 7. A capsule containing a composition according to any one of claims ito i 6.
  18. 18. A medical device comprising a composition according to any one of claims ito i4.
  19. 19. A composition, capsule or medical device according to any one of claims 1 to 18 for use in one or more of: binding lipids passing through the gastrointestinal tract and thereby preventing or reducing absorption of the lipids; reducing the cravings for fat; and reducing fat mass in the body.
  20. 20. A composition, capsule or medical device according to any of claims 1 to 18 for reducing obesity.
  21. 21. A composition as claimed in any of claims 1 to 16 for use in the treatment of obesity.
  22. 22. A method of reducing obesity comprising administration of a composition, capsule or medical device of claims ito 18.
  23. 23. A method of assisting weight loss comprising administration of a composition, capsule or medical device of claims 1 to 18.
  24. 24. Use of a composition as claimed in any of claims ito 16 for the manufacture of a medicament for treating obesity.
GB1205152.0A 2012-03-23 2012-03-23 A composition for the treatment of obesity Withdrawn GB2501242A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1205152.0A GB2501242A (en) 2012-03-23 2012-03-23 A composition for the treatment of obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1205152.0A GB2501242A (en) 2012-03-23 2012-03-23 A composition for the treatment of obesity

Publications (2)

Publication Number Publication Date
GB201205152D0 GB201205152D0 (en) 2012-05-09
GB2501242A true GB2501242A (en) 2013-10-23

Family

ID=46087021

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1205152.0A Withdrawn GB2501242A (en) 2012-03-23 2012-03-23 A composition for the treatment of obesity

Country Status (1)

Country Link
GB (1) GB2501242A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067936A1 (en) * 2013-11-05 2015-05-14 Optibiotix Limited Composition
LU92458B1 (en) * 2014-05-20 2015-11-23 Dyna Sarl SLIMMING COMPOSITION
BE1021980B1 (en) * 2014-05-20 2016-02-01 Dyna + Sarl SLIMMING COMPOSITION.
RU2808338C1 (en) * 2022-09-27 2023-11-28 Общество с ограниченной ответственностью "Клиника психотерапии и восстановительной медицины" (ООО "Клиника психотерапии и восстановительной медицины") Weight reduction method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034650A1 (en) * 2003-10-17 2005-04-21 Diet Formulations Ltd. Weight-loss supplement
EP1679009A1 (en) * 2005-01-05 2006-07-12 ABOCA S.p.A. Pharmaceutical and dietetic compositions based on vegetable fibres
US20060269535A1 (en) * 2005-05-31 2006-11-30 Naidu A S Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
CN101791079A (en) * 2010-03-12 2010-08-04 苟春虎 Capsule for reducing weight and beautifying features
US20120034323A1 (en) * 2010-08-03 2012-02-09 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
GB2490126A (en) * 2011-04-18 2012-10-24 Jeremy John Stephens Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034650A1 (en) * 2003-10-17 2005-04-21 Diet Formulations Ltd. Weight-loss supplement
EP1679009A1 (en) * 2005-01-05 2006-07-12 ABOCA S.p.A. Pharmaceutical and dietetic compositions based on vegetable fibres
US20060269535A1 (en) * 2005-05-31 2006-11-30 Naidu A S Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
CN101791079A (en) * 2010-03-12 2010-08-04 苟春虎 Capsule for reducing weight and beautifying features
US20120034323A1 (en) * 2010-08-03 2012-02-09 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
GB2490126A (en) * 2011-04-18 2012-10-24 Jeremy John Stephens Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067936A1 (en) * 2013-11-05 2015-05-14 Optibiotix Limited Composition
US10863763B2 (en) 2013-11-05 2020-12-15 Optibiotix Limited Prebiotic compositions and uses thereof
LU92458B1 (en) * 2014-05-20 2015-11-23 Dyna Sarl SLIMMING COMPOSITION
BE1021980B1 (en) * 2014-05-20 2016-02-01 Dyna + Sarl SLIMMING COMPOSITION.
RU2808338C1 (en) * 2022-09-27 2023-11-28 Общество с ограниченной ответственностью "Клиника психотерапии и восстановительной медицины" (ООО "Клиника психотерапии и восстановительной медицины") Weight reduction method

Also Published As

Publication number Publication date
GB201205152D0 (en) 2012-05-09

Similar Documents

Publication Publication Date Title
EP1679009B1 (en) Pharmaceutical and dietetic compositions based on vegetable fibres
US5932561A (en) Dietary composition with lipid binding properties for weight management and serum lipid reduction
CA2967284C (en) A dietary fibre composition
KR102384233B1 (en) Composition comprising okra for use in reducing dietary fat absorption
AU2011251041B2 (en) Composition for reducing absorption of dietary fat
CZ39699A3 (en) Mixtures of vegetable carbohydrates functioning as foodstuff complements
WO2006055711A1 (en) Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
US20100215687A1 (en) Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
GB2501242A (en) A composition for the treatment of obesity
EP3691474A1 (en) Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
Jung et al. L-ascorbic acid addition to chitosan reduces body weight in overweight women
Preuss et al. Chitosan as a dietary supplement for weight loss: a review
US20210236537A1 (en) High porosity cellulosic structures and methods of treatment therewith
EP3225239B1 (en) Body weight control preparation based on chitosan and cellulose
GB2490126A (en) Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption
Jun et al. Anti-obesity effects of chitosan and psyllium husk with L-ascorbic acid in guinea pigs
Rasmussen et al. Chitin and chitosan
CN1318316A (en) Immunity-regulating and fatigue-resisting health food
GB2501241A (en) A composition for reducing obesity
WO2023112974A1 (en) Hypertension-improving agent containing seaweed extract, and functional food, quasi-drug and drug containing hypertension-improving agent
Mukerjee Cholesterol Lowering Effects Of Psyllium Husk
Singh et al. Development of fiber rich powder and effect of supplementation on constipation
CN113194748A (en) Human dietary supplement and method for treating digestive system and immune related disorders

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)